Grafa News and Videos — Page 727

Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.

Best Buy (NYSE:BBY) announced that its Board of Directors has authorized the payment of a regular quarterly cash dividend of $0.96 per common share, maintaining the electronics retailer's commitment to its ongoing capital return program.

CoStar Group (NASDAQ:CSGP) has entered into a definitive agreement to acquire Zonda, a prominent provider of new home construction data, homebuilder software, and residential marketplaces, for $800 million in cash.

Pfizer (NYSE:PFE) announced unprecedented seven-year follow-up results from its Phase 3 CROWN trial, revealing that its oncology drug Lorbrena significantly extended progression-free survival in patients with a specific, aggressive form of lung cancer.

AbbVie (NYSE:ABBV) has secured authorization from the European Commission for an expanded label of its oncology drug VENCLYXTO (venetoclax) to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).

Lowe’s Companies (NYSE:LOW) authorized a 4% increase to its quarterly cash dividend, extending a multi-decade track record of annual payout increases and signaling confidence in its steady cash generation capabilities.

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.

The Buckle (NYSE:BKE) reported a significant increase in first-quarter profitability, driven by steady brick-and-mortar sales growth and an injection of cash from a finalized legal settlement.

International Flavors & Fragrances (NYSE:IFF) agreed to sell its Food Ingredients division to funds advised by CVC Capital Partners in a transaction valuing the unit at approximately $4.3 billion.